Adopt ‘pop-up’ model to boost clinical trials, UK review argues
The head of a review examining the reasons for a dramatic drop in clinical trials in the UK is urging the government to bring research out of overwhelmed hospitals and into pop-up locations, potentially modelled on those used for Covid-19 vaccinations.
James O’Shaughnessy, former life sciences and innovation minister, has been investigating the 41 per cent fall in the number of industry clinical trials in Britain since 2017.
Novartis scrapped a major trial late last year that would have enrolled 40,000 patients, after a slow rollout of its drug to lower cholesterol. People close to the programme said many GPs had been reluctant to prescribe it, despite the high-profile partnership with the NHS.
This story originally appeared on: Financial Times - Author:Hannah Kuchler
